Nebula Research & Development LLC Purchases 57,263 Shares of CVS Health Co. (NYSE:CVS)

Nebula Research & Development LLC raised its holdings in shares of CVS Health Co. (NYSE:CVS - Free Report) by 322.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,021 shares of the pharmacy operator's stock after acquiring an additional 57,263 shares during the quarter. CVS Health makes up 0.4% of Nebula Research & Development LLC's investment portfolio, making the stock its 27th largest holding. Nebula Research & Development LLC's holdings in CVS Health were worth $3,368,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Ridgewood Investments LLC grew its stake in shares of CVS Health by 255.7% in the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator's stock valued at $28,000 after buying an additional 450 shares in the last quarter. Stonebridge Financial Group LLC bought a new stake in shares of CVS Health in the 4th quarter valued at approximately $28,000. Hopwood Financial Services Inc. bought a new stake in shares of CVS Health in the 4th quarter valued at approximately $29,000. Financial Perspectives Inc grew its stake in shares of CVS Health by 137.5% in the 4th quarter. Financial Perspectives Inc now owns 805 shares of the pharmacy operator's stock valued at $36,000 after buying an additional 466 shares in the last quarter. Finally, MidAtlantic Capital Management Inc. grew its stake in shares of CVS Health by 112.1% in the 4th quarter. MidAtlantic Capital Management Inc. now owns 827 shares of the pharmacy operator's stock valued at $37,000 after buying an additional 437 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Trading Down 0.6 %

NYSE:CVS traded down $0.41 during trading hours on Monday, hitting $64.91. The stock had a trading volume of 7,700,036 shares, compared to its average volume of 11,825,202. CVS Health Co. has a one year low of $43.56 and a one year high of $71.45. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81. The company has a market cap of $81.84 billion, a price-to-earnings ratio of 17.74, a P/E/G ratio of 0.98 and a beta of 0.57. The business's 50 day moving average is $66.48 and its 200-day moving average is $58.77.

CVS Health (NYSE:CVS - Get Free Report) last issued its earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Sell-side analysts anticipate that CVS Health Co. will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 4.10%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health's dividend payout ratio (DPR) is presently 72.68%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on CVS shares. Leerink Partnrs raised CVS Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 12th. Wolfe Research upped their price target on CVS Health from 67.00 to 70.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. StockNews.com upgraded CVS Health from a "sell" rating to a "hold" rating in a research note on Thursday, February 13th. Edward Jones upgraded CVS Health from a "hold" rating to a "buy" rating in a research note on Thursday, January 30th. Finally, UBS Group cut their target price on CVS Health from $62.00 to $59.00 and set a "neutral" rating for the company in a research note on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, CVS Health presently has a consensus rating of "Moderate Buy" and an average target price of $71.83.

Insider Buying and Selling

In other CVS Health news, SVP James David Clark sold 7,513 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael F. Mahoney purchased 30,000 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.22% of the stock is currently owned by corporate insiders.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.